

Inventor: William D. Huse  
Serial No.: 09/016,061  
Filed: January 30, 1998  
Page 3

Please add the following new claims:

<sup>7</sup> ~~129~~. (New) The antibody of claim <sup>6</sup> ~~110~~, or functional fragment thereof, comprising a V<sub>H</sub> CDR1 referenced as SEQ ID NO:48.

<sup>8</sup> ~~130~~. (New) The antibody of claim <sup>7</sup> ~~129~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub>, and scFV.

<sup>9</sup> ~~131~~. (New) The antibody of claim <sup>6</sup> ~~110~~, or functional fragment thereof, comprising a V<sub>H</sub> CDR1 referenced as SEQ ID NO:50.

<sup>10</sup> ~~132~~. (New) The antibody of claim <sup>6</sup> ~~131~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub>, and scFV.

<sup>11</sup> ~~133~~. (New) The antibody of claim <sup>6</sup> ~~110~~, or functional fragment thereof, comprising a V<sub>H</sub> CDR1 referenced as SEQ ID NO:52.

<sup>12</sup> ~~134~~. (New) The antibody of claim <sup>6</sup> ~~133~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub>, and scFV.

<sup>13</sup> ~~135~~. (New) The antibody of claim <sup>6</sup> ~~110~~, or functional fragment thereof, comprising a V<sub>H</sub> CDR2 referenced as SEQ ID NO:54.

138

E

Inventor: William D. Huse  
Serial No.: 09/016,061  
Filed: January 30, 1998  
Page 4

<sup>14</sup>  
~~136.~~ (New) The antibody of claim <sup>13</sup>~~135~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

<sup>15</sup>  
~~137.~~ (New) The antibody of claim <sup>6</sup>~~110~~, or functional fragment thereof, comprising a V<sub>H</sub> CDR2 referenced as SEQ ID NO:56.

<sup>16</sup>  
~~138.~~ (New) The antibody of claim <sup>15</sup>~~137~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

E3  
<sup>17</sup>  
~~139.~~ (New) The antibody of claim <sup>6</sup>~~110~~, or functional fragment thereof, comprising a V<sub>H</sub> CDR2 referenced as SEQ ID NO:58.

<sup>18</sup>  
~~140.~~ (New) The antibody of claim <sup>17</sup>~~139~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

<sup>19</sup>  
~~141.~~ (New) The antibody of claim <sup>6</sup>~~110~~, or functional fragment thereof, comprising a V<sub>H</sub> CDR3 referenced as SEQ ID NO:60.

<sup>20</sup>  
~~142.~~ (New) The antibody of claim <sup>19</sup>~~141~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

139

E

Inventor: William D. Huse  
Serial No.: 09/016,061  
Filed: January 30, 1998  
Page 5

*v1* ~~143.~~ (New) The antibody of claim ~~110~~<sup>6</sup>, or functional fragment thereof, comprising a V<sub>H</sub> CDR3 referenced as SEQ ID NO:62.

*v2* ~~144.~~ (New) The antibody of claim ~~143~~<sup>6</sup>, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub>, and scFV.

*v3* ~~145.~~ (New) The antibody of claim ~~110~~<sup>6</sup>, or functional fragment thereof, comprising a V<sub>H</sub> CDR3 referenced as SEQ ID NO:64.

*E3* *v4* ~~146.~~ (New) The antibody of claim ~~145~~<sup>6</sup>, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub>, and scFV.

*v5* ~~147.~~ (New) The antibody of claim ~~110~~<sup>6</sup>, or functional fragment thereof, comprising a V<sub>H</sub> CDR3 referenced as SEQ ID NO:66.

*v6* ~~148.~~ (New) The antibody of claim ~~147~~<sup>6</sup>, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub>, and scFV.

*v7* ~~149.~~ (New) The antibody of claim ~~110~~<sup>6</sup>, or functional fragment thereof, comprising a V<sub>H</sub> CDR3 referenced as SEQ ID NO:68.

140

E

Inventor: William D. Huse  
Serial No.: 09/016,061  
Filed: January 30, 1998  
Page 6

<sup>27</sup>  
~~28~~ <sup>150.</sup> (New) The antibody of claim ~~149~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

<sup>28</sup> <sup>151.</sup> (New) The antibody of claim ~~149~~, or functional fragment thereof, comprising a V<sub>H</sub> CDR3 referenced as SEQ ID NO:70.

<sup>29</sup> <sup>152.</sup> (New) The antibody of claim ~~151~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

<sup>E3</sup> <sup>30</sup> ~~153.~~ (New) The antibody of claim ~~149~~, or functional fragment thereof, comprising a V<sub>H</sub> CDR3 referenced as SEQ ID NO:72.

<sup>31</sup> <sup>154.</sup> (New) The antibody of claim ~~153~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

<sup>32</sup> <sup>155.</sup> (New) The antibody of claim ~~149~~, or functional fragment thereof, comprising a V<sub>H</sub> CDR3 referenced as SEQ ID NO:74.

<sup>33</sup> <sup>156.</sup> (New) The antibody of claim ~~155~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

141

E

Inventor: William D. Huse  
Serial No.: 09/016,061  
Filed: January 30, 1998  
Page 7

<sup>35</sup><sub>157</sub>. (New) The antibody of claim <sup>6</sup>~~110~~, or functional fragment thereof, comprising a V<sub>H</sub> CDR3 referenced as SEQ ID NO:76.

<sup>36</sup><sub>158</sub>. (New) The antibody of claim <sup>35</sup><sub>157</sub>, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub>, and scFV.

<sup>37</sup><sub>159</sub>. (New) The antibody of claim <sup>6</sup>~~110~~, or functional fragment thereof, comprising a V<sub>H</sub> CDR3 referenced as SEQ ID NO:78.

<sup>38</sup><sub>160</sub>. (New) The antibody of claim <sup>37</sup><sub>159</sub>, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub>, and scFV.

<sup>39</sup><sub>161</sub>. (New) The antibody of claim <sup>6</sup>~~110~~, or functional fragment thereof, comprising a V<sub>H</sub> CDR3 referenced as SEQ ID NO:80.

<sup>40</sup><sub>162</sub>. (New) The antibody of claim <sup>39</sup><sub>161</sub>, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub>, and scFV.

<sup>41</sup><sub>163</sub>. (New) The antibody of claim <sup>6</sup>~~110~~, or functional fragment thereof, comprising a V<sub>H</sub> CDR3 referenced as SEQ ID NO:94.

142

E

Inventor: William D. Huse  
Serial No.: 09/016,061  
Filed: January 30, 1998  
Page 8

<sup>41</sup>  
~~44~~ 164. (New) The antibody of claim ~~163~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

<sup>42</sup>  
~~43~~ 165. (New) The antibody of claim ~~110~~, or functional fragment thereof, comprising a V<sub>H</sub> CDR3 referenced as SEQ ID NO:96.

<sup>44</sup>  
~~45~~ 166. (New) The antibody of claim ~~165~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

<sup>45</sup>  
~~46~~ 167. (New) The antibody of claim ~~110~~, or functional fragment thereof, comprising a V<sub>H</sub> CDR3 referenced as SEQ ID NO:98.

<sup>46</sup>  
~~47~~ 168. (New) The antibody of claim ~~167~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

<sup>47</sup>  
~~48~~ 169. (New) The antibody of claim ~~110~~, or functional fragment thereof, comprising a V<sub>H</sub> CDR3 referenced as SEQ ID NO:100.

<sup>48</sup>  
~~49~~ 170. (New) The antibody of claim ~~169~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

143

E

Inventor: William D. Huse  
Serial No.: 09/016,061  
Filed: January 30, 1998  
Page 9

<sup>49</sup>  
~~171.~~ (New) The antibody of claim ~~170~~<sup>6</sup>, or functional fragment thereof, comprising a V<sub>L</sub> CDR1 referenced as SEQ ID NO:82.

<sup>50</sup>  
~~172.~~ (New) The antibody of claim ~~171~~<sup>49</sup>, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub>, and scFV.

<sup>51</sup>  
~~173.~~ (New) The antibody of claim ~~170~~<sup>6</sup>, or functional fragment thereof, comprising a V<sub>L</sub> CDR2 referenced as SEQ ID NO:84.

<sup>52</sup>  
~~174.~~ (New) The antibody of claim ~~173~~<sup>51</sup>, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub>, and scFV.

<sup>53</sup>  
~~175.~~ (New) The antibody of claim ~~170~~<sup>6</sup>, or functional fragment thereof, comprising a V<sub>L</sub> CDR3 referenced as SEQ ID NO:86.

<sup>54</sup>  
~~176.~~ (New) The antibody of claim ~~175~~<sup>53</sup>, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub>, and scFV.

<sup>55</sup>  
~~177.~~ (New) The antibody of claim ~~170~~<sup>6</sup>, or functional fragment thereof, comprising a V<sub>L</sub> CDR3 referenced as SEQ ID NO:88.

144

E

Inventor: William D. Huse  
Serial No.: 09/016,061  
Filed: January 30, 1998  
Page 10

*56*  
*178.* (New) The antibody of claim *177*, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

*57*  
*179.* (New) The antibody of claim *170*, or functional fragment thereof, comprising a V<sub>L</sub> CDR3 referenced as SEQ ID NO:90.

*58*  
*180.* (New) The antibody of claim *179*, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.  
*E3*

*59*  
*181.* (New) The antibody of claim *170*, or functional fragment thereof, comprising a V<sub>L</sub> CDR3 referenced as SEQ ID NO:92.

*60*  
*182.* (New) The antibody of claim *181*, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

*61*  
*183.* (New) The antibody of claim *170*, or functional fragment thereof, comprising the combination of CDRs V<sub>L</sub> CDR1 referenced as SEQ ID NO:82 and V<sub>H</sub> CDR3 referenced as SEQ ID NO:68.

*62*  
*184.* (New) The antibody of claim *183*, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

*145*

*E*

Inventor: William D. Huse  
Serial No.: 09/016,061  
Filed: January 30, 1998  
Page 11

6

<sup>63</sup>  
~~185.~~ (New) The antibody of claim ~~110~~, or functional fragment thereof, comprising the combination of CDRs V<sub>L</sub> CDR1 referenced as SEQ ID NO:82, V<sub>H</sub> CDR2 referenced as SEQ ID NO:56 and V<sub>H</sub> CDR3 referenced as SEQ ID NO:68.

63

<sup>64</sup>  
~~186.~~ (New) The antibody of claim ~~185~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

6

<sup>65</sup>  
~~187.~~ (New) The antibody of claim ~~110~~, or functional fragment thereof, comprising the combination of CDRs V<sub>L</sub> CDR1 referenced as SEQ ID NO:82, V<sub>H</sub> CDR2 referenced as SEQ ID NO:56 and V<sub>H</sub> CDR3 referenced as SEQ ID NO:72.

E3

65

<sup>66</sup>  
~~188.~~ (New) The antibody of claim ~~187~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

6

<sup>67</sup>  
~~189.~~ (New) The antibody of claim ~~110~~, or functional fragment thereof, comprising the combination of CDRs V<sub>L</sub> CDR1 referenced as SEQ ID NO:82, V<sub>H</sub> CDR2 referenced as SEQ ID NO:56 and V<sub>H</sub> CDR3 referenced as SEQ ID NO:70.

67

<sup>68</sup>  
~~190.~~ (New) The antibody of claim ~~189~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

6

<sup>69</sup>  
~~191.~~ (New) The antibody of claim ~~110~~, or functional fragment thereof, comprising the combination of CDRs V<sub>L</sub> CDR1

146

E

Inventor: William D. Huse  
Serial No.: 09/016,061  
Filed: January 30, 1998  
Page 12

referenced as SEQ ID NO:82 and V<sub>H</sub> CDR3 referenced as SEQ ID NO:72.

~~70~~ 192. (New) The antibody of claim ~~191~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

~~71~~ 193. (New) The antibody of claim ~~190~~, or functional fragment thereof, comprising the combination of CDRs V<sub>L</sub> CDR3 referenced as SEQ ID NO:86, V<sub>H</sub> CDR2 referenced as SEQ ID NO:56 and V<sub>H</sub> CDR3 referenced as SEQ ID NO:68.

E3  
~~72~~ 194. (New) The antibody of claim ~~193~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

~~73~~ 195. (New) The antibody of claim ~~190~~, or functional fragment thereof, comprising the combination of CDRs V<sub>L</sub> CDR3 referenced as SEQ ID NO:90, V<sub>H</sub> CDR2 referenced as SEQ ID NO:56 and V<sub>H</sub> CDR3 referenced as SEQ ID NO:94.

~~74~~ 196. (New) The antibody of claim ~~195~~, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

~~75~~ 197. (New) The antibody of claim ~~190~~, or functional fragment thereof, comprising the combination of CDRs V<sub>L</sub> CDR3 referenced as SEQ ID NO:90 and V<sub>H</sub> CDR3 referenced as SEQ ID NO:68.

147

E

Inventor: William D. Huse  
Serial No.: 09/016,061  
Filed: January 30, 1998  
Page 13

*76* 198. (New) The antibody of claim *197*, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

*77* 199. (New) The antibody of claim *110*, or functional fragment thereof, comprising the combination of CDRs V<sub>L</sub> CDR3 referenced as SEQ ID NO:90, V<sub>H</sub> CDR2 referenced as SEQ ID NO:56 and V<sub>H</sub> CDR3 referenced as SEQ ID NO:68.

*E3* *78* 200. (New) The antibody of claim *199*, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

*79* 201. (New) The antibody of claim *110*, or functional fragment thereof, comprising the combination of CDRs V<sub>L</sub> CDR1 referenced as SEQ ID NO:82, V<sub>H</sub> CDR2 referenced as SEQ ID NO:56 and V<sub>H</sub> CDR3 referenced as SEQ ID NO:94.

*80* 202. (New) The antibody of claim *201*, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

*81* 203. (New) The antibody of claim *110*, or functional fragment thereof, comprising the combination of CDRs V<sub>L</sub> CDR3 referenced as SEQ ID NO:90, V<sub>H</sub> CDR2 referenced as SEQ ID NO:56 and V<sub>H</sub> CDR3 referenced as SEQ ID NO:96.

148

*E*

Inventor: William D. Huse  
Serial No.: 09/016,061  
Filed: January 30, 1998  
Page 14

*82*  
*204.* (New) The antibody of claim *203*, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub>, and scFV.

*83*  
*205.* (New) The antibody of claim *110*, or functional fragment thereof, comprising the combination of CDRs V<sub>L</sub> CDR3 referenced as SEQ ID NO:90 and V<sub>H</sub> CDR3 referenced as SEQ ID NO:94.

*E3*  
*84*  
*206.* (New) The antibody of claim *205*, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub>, and scFV.

*85*  
*207.* (New) The antibody of claim *110*, or functional fragment thereof, comprising the combination of CDRs V<sub>L</sub> CDR3 referenced as SEQ ID NO:90 and V<sub>H</sub> CDR3 referenced as SEQ ID NO:98.

*86*  
*208.* (New) The antibody of claim *207*, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub>, and scFV.

*87*  
*209.* (New) The antibody of claim *110*, or functional fragment thereof, comprising the combination of CDRs V<sub>L</sub> CDR3 referenced as SEQ ID NO:90, V<sub>H</sub> CDR2 referenced as SEQ ID NO:56 and V<sub>H</sub> CDR3 referenced as SEQ ID NO:100.

| 49

*E*

Inventor: William D. Huse  
Serial No.: 09/016,061  
Filed: January 30, 1998  
Page 15

*88*  
*210.* (New) The antibody of claim *209*, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub> and scFV.

*89*  
*E3*  
*211.* (New) A grafted antibody exhibiting selective binding affinity to  $\alpha_v\beta_3$ , or a functional fragment thereof, comprising one or more CDRs having at least one amino acid substitution in one or more CDRs of the heavy chain variable region polypeptide referenced as SEQ ID NO:6 or the light chain variable region polypeptide referenced as SEQ ID NO:8, said antibody or functional fragment thereof having increased integrin  $\alpha_v\beta_3$  binding activity, integrin  $\alpha_v\beta_3$  binding specificity or integrin  $\alpha_v\beta_3$ -inhibitory activity relative to parental antibody comprising a heavy chain variable region polypeptide referenced as SEQ ID NO:6 and a light chain variable region amino acid sequence referenced as SEQ ID NO:8.

*90*  
*212.* (New) The grafted antibody of claim *211*, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)<sub>2</sub>, and scFV.

*a1*  
*213.* (New) The grafted antibody of claim *211*, wherein said grafted antibody comprises at least one amino acid substitution in two or more of said CDRs.

*91*  
*214.* (New) The grafted antibody of claim *211*, wherein at least one of said CDRs has two or more amino acid substitutions.